(Corrects typo in the first paragraph)
Dec 5 (Reuters) - AstraZeneca Plc and Merck & Co Inc
said on Thursday that their drug, Lynparza, won approval
in China as a first line treatment for a form of ovarian cancer.
The approval in China is based on the results from a
late-stage study in which Lynparza lowered the risk of disease
progression or death by 70% when compared to
placebo.
Lynparza is currently approved in 65 countries for the
maintenance treatment of platinum-sensitive relapsed ovarian
cancer, the companies said.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by
Bernard Orr)
Astrazeneca (AZN)
